ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2022 and some content may be unavailable. To unlock all content for 2022, please visit the archives.

Abstract: SA-PO430

Association Between Sleep and COVID-19 Vaccination Response in Hemodialysis Patients

Session Information

Category: Dialysis

  • 701 Dialysis: Hemodialysis and Frequent Dialysis

Authors

  • Han, Maggie, Renal Research Institute, New York, New York, United States
  • Wang, Xiaoling, Renal Research Institute, New York, New York, United States
  • Ye, Xiaoling, Renal Research Institute, New York, New York, United States
  • Dong, Zijun, Renal Research Institute, New York, New York, United States
  • Thwin, Ohnmar, Renal Research Institute, New York, New York, United States
  • Patel, Amrish U., Renal Research Institute, New York, New York, United States
  • Tisdale, Lela, Renal Research Institute, New York, New York, United States
  • Wang, Lin-Chun, Renal Research Institute, New York, New York, United States
  • Ren, Sarah, Renal Research Institute, New York, New York, United States
  • Rivera Fuentes, Lemuel, Renal Research Institute, New York, New York, United States
  • Zhang, Hanjie, Renal Research Institute, New York, New York, United States
  • Kotanko, Peter, Renal Research Institute, New York, New York, United States
Background

Hemodialysis (HD) patients are less likely to mount a response to the COVID-19 vaccination (CoVac). Poor sleep is associated with blunted vaccination response in the general population. We aim to explore the association between CoVac and sleep quality (SQ) in HD patients.

Methods

Patients from 3 HD clinics were enrolled if they were ≥18 years and able to give written consent. Patients were administered the Insomnia Severity Index (ISI) and the Pittsburg Sleep Quality Index (PSQI). Blood specimen were collected after the primary series of COVID-19 vaccination. SARS-CoV-2 neutralization antibodies (nAB) were assayed using the GenScript SARS-CoV-2 Surrogate Virus Neutralization Test Kit (Cat#L00847-A). nAB titers are presented as Unit/ml on a natural log scale. PSQI scores of >5 were categorized as poor SQ and ≤5 as good SQ. ISI scores were grouped as no clinically significant insomnia (NI; score 0-7), subthreshold insomnia (SI; score 8-14), and clinical insomnia (CI; score 14-28). T-test and ANOVA analysis were performed on PSQI and ISI scores, respectively, to determine the statistical association between SQ and nAB levels

Results

58 patients were included (60±9 years old, HD vintage 4.7±4.5 years, 62% male, 66% Black, 21% Hispanic). In the PSQI, 72% (n=42) had poor SQ. In the ISI, 52% = NI, 31% = SI, and 17% CI. Box plots of nAB levels with median and IQR are shown in Fig. 1. There is no association between SQ and nAB levels.

Conclusion

There is no association between SQ and CoVac response. Given the immune dysfunction in this population, any modifying effect SQ has on CoVac, as observed in the general population, is unlikely. Other methods of improving CoVac response in this vulnerable population should be explored.

Funding

  • Commercial Support –